More great news for Combat’s #HIVEC treatment of #bladdercancer from @BrantInman and team at @ASCO meeting.
“Bladder pressure dramatically improves the extent of gemcitabine penetration into the bladder wall”
https://meetinglibrary.asco.org/record/194854/abstract
Many thanks to the team @DukeUrology 👏🏻👏🏻👏🏻
Excellent to hear this. So happy our machine is working to treat patients in Bristol. @CombatCancer #HIVEC #bladdercancer @NorthBristolNHS
Here I go again, this treatment is amazing and I’m so grateful to @NorthBristolNHS #urology for providing this ‘maintenance’ #bladdercancer @CombatCancer @Actionbladderca
Here I go again, this treatment is amazing and I’m so grateful to @NorthBristolNHS #urology for providing this ‘maintenance’ #bladdercancer @CombatCancer @Actionbladderca
@alarjosan @HUReinaSofia @IMIBIC @GECOP_ @operarelcancer @SPeritoneum @aecirujanos @ESSOnews @Hospital_FJD Congrats @alarjosan and team!
Proud to be working with you!
👏🏻👏🏻👏🏻👏🏻👏🏻
Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html
Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html
📢NEXT WEEK📢Prophylactic #peritoneal Management of High-Risk #ColonCancer
🗓️3 NOV-18.30 CEST
🗣Dr @AndreasBrandl8, Dr @alarjosan, Dr Diane Goéré & Dr Pieter Tanis ➡️https://lnkd.in/gNsACYN
#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer @CombatCancer
They don’t do an emoji for HIPEC with agitation bubbles of CO2.
Is this close enough @alarjosan?
🛁🛁🛁🛁🛁
Laparoscopic cytoreductive surgery and HIPEC for a limited low-grade pseudomyxoma peritonei.
Performed by Dr @alarjosan and team at @HUReinaSofia
👏🏻👏🏻👏🏻👏🏻
📢Webinar Alert📢
Prophylactic #peritoneal Management of High-Risk #ColonCancer
🗓️3 November-18.30 CEST
🗣Dr @AndreasBrandl8, Dr Alvaro-Arjona-Sanchez, Dr Diane Goéré & Dr Pieter Tanis
👉https://www.essoweb.org/courses/
#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer
Three of our portfolio companies (@CombatCancer @LightpointMed
and @entiahealth) named by Coutts as "#medtech marvels supporting the NHS"
Coutts backs med-tech marvels supporting NHS
Meet four of the firms forging the future of health care with help from our clients
www.coutts.com
To register for this Friday's webinar (5-6 UK) click on the Eventbrite link
#HIVEC #BCGUnresponsive
HIVEC for BCG Unresponsive
Find out more about HIVEC in BCG Unresponsive Patients with Clinical Discussion and Live Q&A. EAU20 Presented Data.
www.eventbrite.co.uk
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
40 patients took part in the study, split into two groups – one which received the HIVEC™ treatment prior to a resection of the bladder, and another which received HIVEC after resection of the bladder.
97% of the patients were able to complete the full course of HIVEC treatments, and the majority of participants responded well to the treatment and show low rates of recurrence. Furthermore, the majority of the side-effects were low grade and had very little effect on the treatment plan.
Click Here to read the full article
Click Here to read the interview with the research author
